Questions And Answers About Bristol Myers Squibb's Consolidated Site Payments Strategy
Source: IQVIA Technologies

Clinical trial payments can make or break sponsor-site relationships. IQVIA Technologies heard both perspectives on this issue from industry leaders George Kourtsounis, Senior Director for Clinical Trial Contracts and Grants at Bristol Myers Squibb (BMS); and Casey Orvin, Chief Commercial Officer at CenExel Clinical Research and former President of the Society for Clinical Research Sites during a recent webinar. During a Q&A session, these industry leaders lent their expertise to the following questions:
- What kind of oversight is in place at BMS, and what does that tell BMS about efficiencies and quality?
- Sponsors struggle with forecasting, as capabilities vary significantly across CROs. How does BMS feel about its current grant forecasting abilities?
- How can sites ensure they receive timely payments?
- What data sources are you receiving to forecast payments, and is it associated with specific trials?
- How has IQVIA CTP made payments easier for BMS?
access the Q&A!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
IQVIA Technologies
This website uses cookies to ensure you get the best experience on our website. Learn more